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Abstract
Background: Akt regulates various cellular processes, including cell growth, survival, and metabolism. Recently,
Akt’s role in neurite outgrowth has also emerged. We thus aimed to identify neuronal function-related genes that
are regulated by Akt.
Methods: We performed suppression subtractive hybridization on two previously established PC12 sublines, one of
which overexpresses the wild-type (WT) form and the other, the dominant-negative (DN) form of Akt. These
sublines respond differently to NGF’s neuronal differentiation effect.
Results: A variety of genes was identified and could be classified into several functional groups, one of which was
developmental processes. Two genes involved in neuronal differentiation and function were found in this group. v-
Maf musculoaponeurotic fibrosarcoma oncogene homolog K (MafK) induces the neuronal differentiation of PC12
cells and immature telencephalon neurons, and synaptotagmin I (SytI) is essential for neurotransmitter release.
Another gene, syntenin-1 (Syn-1) was also recognized in the same functional group into which MafK and SytI were
classified. Syn-1 has been reported to promote the formation of membrane varicosities in neurons. Quantitative
reverse transcription polymerase chain reaction analyses show that the transcript levels of these three genes were
lower in PC12 (WT-Akt) cells than in parental PC12 and PC12 (DN-Akt) cells. Furthermore, treatment of PC12 (WT-
Akt) cells with an Akt inhibitor resulted in the increase of the expression of these genes and the improvement of
neurite outgrowth. These results indicate that dominant-negative or pharmacological inhibition of Akt increases the
expression of MafK, SytI, and Syn-1 genes. Using lentiviral shRNA to knock down endogenous Syn-1 expression, we
demonstrated that Syn-1 promotes an increase in the numbers of neurites and branches.
Conclusions: Taken together, these results indicate that Akt negatively regulates the expression of MafK, SytI, and
Syn-1 genes that all participate in regulating neuronal integrity in some way or another.
Background
Akt (also termed “protein kinase B’)m e d i a t e sav a r i e t y
of biological responses to insulin, cytokines, and numer-
ous growth factors. As such, Akt has been well recog-
nized as an important regulator for multiple biological
processes, including metabolism, cell size, apoptosis, and
cell cycle progression [1]. Recently, the importance of
Akt in neuronal functions beyond neuronal protection
against apoptotic insults has emerged. Akt was reported
to inhibit the neuronal differentiation of hippocampal
neural progenitor cells [2] and of PC12 cells [3-5]. Simi-
larly, Akt activity was found to be sustainedly augmen-
ted when neurite outgrowth of PC12 cells was inhibited
by CSK overexpression [6].
These actions of Akt are evoked by phosphorylating
its substrates and thus regulating the activity of proteins
and the expression of genes. A number of Akt substrates
and Akt-regulated genes have been identified, but these
are mostly involved in metabolism, cell size, apoptosis,
and cell cycle progression. These include Gsk3, BAD,
p21
Cip1/WAF1,p 2 7
Kip1, and certain transcription factors
and transcription factor regulators such as cAMP-
response element binding protein (CREB), the FOXO
family of Forkhead transcription factors, IB kinase, and
* Correspondence: sungilyang@kku.ac.kr
2Department of Pharmacology, School of Medicine, Konkuk University, Seoul,
Republic of Korea
Ro et al. Journal of Biomedical Science 2010, 17:18
http://www.jbiomedsci.com/content/17/1/18
© 2010 Ro et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.Mdm2 [7-16]. Through these transcription factors and
regulators, Akt regulates the transcription of genes that
possess anti-apoptotic, pro-survival or pro-apoptotic
functions, such as Bcl-2, Bcl-XL, A1, and FasL [15,17,18].
Unlike these Akt-regulated genes in apoptosis and sur-
vival, however, hardly any genes implicated in neuronal
differentiation process have been revealed to be regu-
lated by Akt. Therefore, we sought to find Akt-regulated
differentiation genes in rat PC12 pheochromocytoma
cells, which are often used as a model of neuronal dif-
ferentiation. We performed suppression subtractive
hybridization (SSH) on two previously established sub-
clonal PC12 cell lines that ectopically express a wild-
type (WT) or dominant-negative (DN) form of Akt1 [3].
PC12 (WT-Akt) cells barely differentiate in response to
NGF, whereas PC12 (DN-Akt) cells extend their neur-
ites quite well. Approximately seventy genes including
v-maf musculoaponeurotic fibrosarcoma oncogene homo-
log K (MafK), synaptotagmin I (SytI), and syntenin-1
(Syn-1) were recognized as genes expressed at a higher
level in cells that express have PC12 (DN-Akt) cells. We
demonstrated here that knockdown of Syn-1 decreases
the number of neurites per neuritogenic cell and the
percentage of branch-bearing neurites, implicating a
positive role for Syn-1 in neurite outgrowth. Likewise,
MafK and SytI are known to play a role in neuronal dif-
ferentiation and neurotransmitter release, respectively.
By quantitative reverse transcription polymerase chain
reaction (RT-PCR) analysis, we confirmed that PC12
(WT-Akt) cells had a lower level of expression of these
three genes than PC12 (WT-Akt) cells, and also demon-
strated that pharmacological inhibition of Akt causes an
increase in the expression of these genes in PC12 (WT-
Akt) cells. Therefore, it is alleged that Akt downregu-
lates the expression of MafK, SytI,a n dSyn-1 genes, all
of which are positively related to neuronal function.
Methods
Materials
A potent and specific inhibitor of Akt (AKTi-1/2;
naphthyridinone) and the Gsk3b inhibitor TWS119
were purchased from Calbiochem (CA, USA). Actino-
mycin D was from Sigma (MO, USA). Nerve growth
factor (NGF) 2.5 S was obtained from Roche (NJ, USA)
and the iQ™ SYBR® Green Supermix came from Bio-Rad
(CA, USA).
Cell culture
The PC12-derived subclones, PC12 (WT-Akt) and PC12
(DN-Akt), were isolated as previously described [3].
Cells were grown in DMEM containing 10% horse
serum and 5% fetal bovine serum in a 5% CO2 atmo-
sphere. For maintenance of the subclones, 200 μg/ml of
G418 was included in the culture media. Where
indicated, 100 ng/ml of NGF was added to the cultures
in DMEM containing 1% horse serum and 0.5% fetal
calf serum.
SSH
Cells were treated with 100 ng/ml of NGF for 2 hrs.
Total RNA was prepared with the RNeasy kit (Qiagen,
CA, USA) and cDNA was synthesized using the
SMART™ PCR cDNA Synthesis Kit (BD Biosciences,
CA, USA). SSH was carried out with the PCR-Select™
cDNA subtraction kit (BD Biosciences), as described by
the manufacturer. cDNAs synthesized from the total
RNA of PC12 (WT-Akt) and PC12 (DN-Akt) cells were
used as the drivers and testers, respectively. Plasmids
encoding subtracted cDNA were subjected to cycle
sequencing using the ABI PRISM™ 310 genetic analyzer
(Applied Biosystems, CA, USA). The sequences obtained
were used for sequence alignment with the National
Center for Biotechnology Information, GenBank, using a
basic blast search.
Semi-quantitative and quantitative RT-PCR
cDNA was synthesized from RNA using the Omniscript
RT kit (Qiagen) according to the manufacturer’sp r o t o -
col. The cDNA mixture was amplified using PCR with
specific primers (Table 1), and the resulting products
were separated on 2% agarose gel. Quantitative PCR was
r u nu s i n gS Y B Rg r e e nP C Rm a s t e r m i xa n dt h eL i g h t C y -
cler Real-time PCR Detection System (Roche). The num-
ber of amplification steps required to reach the threshold
cycle number (Ct) was computed using LightCycler soft-
ware 4.0 (Roche). To normalize input cDNA, Gapdh was
run separately in all experiments under the same condi-
tions. The expression levels of each gene were normal-
ized against Gapdh using the comparative Ct method.
Inhibitor treatment
Cells were pretreated with the Akt inhibitor AKTi-1/2
(0.1 - 10 μM) or the Gsk3b inhibitor TWS119 (10 μM)
for 3 hrs in DMEM and 1% horse serum and 0.5% fetal
calf serum, prior to treatment with 100 ng/ml of NGF
for either 10 min or 2 hr. For the transcriptional inhibi-
tor actinomycin D, cells were treated with 100 ng/ml of
NGF for 2 hr, followed by 10 μM actinomycin D for 2
hr in the absence of NGF.
Lentivirus vector and infection
The lentiviral shRNA vector was constructed in plasmid
pLV-TH (Dr. Didier Trono, University of Geneva, Gen-
eva, Switzerland). Target sequences for knockdown of
Syn-1 were: shSyn-1#1 (GGATTAGGAGAGCAGA-
GAT), shSyn-1#2 (GTGAGATCAACGGACAGAA).
A nonsilencing control shRNA (shControl) was
GCGTGTACATGCGTGTA. Viral stock was generated
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using a standard calcium phosphate precipitation techni-
que. The appropriate lentiviral vector plasmid (10 μg)
and the packaging vector plasmids (3.5 μg of pMD.G
and 6.5 μgo fp Δ8.2) were co-transfected. Viral superna-
tants were harvested at 48 and 72 hr after transfection
a n df i l t e r e dt h r o u g ha0 . 4 5μm pore size filter. Viral
supernatants were concentrated by centrifugation for 90
min at 50,000 × g and the viral particles were then
resuspended in DMEM containing 10% FBS. Transduc-
tion of PC12 cells was performed at an MOI of 10 in
t h ep r e s e n c eo f4μg/ml polybrene (Sigma), and three
days after infection, knockdown of Syn-1 transcript and
protein was confirmed by quantitative PCR and western
blot analysis.
Evaluation of neurite outgrowth
PC12 (WT-Akt) cells were incubated with DMEM con-
taining 1% horse serum and 0.5% fetal calf serum over-
night and treated with 100 ng/ml of NGF and AKTi-1/2
(0, 0.1, 1 μM). After four days, cells with neurites of at
least two cell body diameters were counted. A minimum
of 50 to 100 cells per field was examined in six to nine
fields. For PC12 (DN-Akt) cells, cells were infected with
lentivirus targeting Syn-1 (shSyn-1#2) or shControl at
an MOI of 10. Three days after infection, 10
4 cells were
plated into a 12-well plate. Cells were incubated with
DMEM containing 1% horse serum and 0.5% fetal calf
serum overnight and treated with NGF for five days.
GFP-expressing neuritogenic cells were examined using
phase-contrast fluorescent microscopy. Ten to fifteen
microscopic fields of cells were randomly chosen, and
cells that had neurites exceeding twice the length of the
cell body were regarded as neuritogenic cells.
Western blot analysis
Cells were lysed as described previously [3,19], and pro-
teins were separated with SDS-10% PAGE and transferred
onto PVDF membranes. Membranes were incubated with
antibodies for Akt (Cell Signaling Technology, MA, USA),
SytI (BD Biosciences), MafK/NF-E2 p18 (Santa Cruz Bio-
technology, CA, USA), Syn-1 (Millipore, CA, USA),
b-catenin (Santa Cruz Biotechnology), and b-Actin
(Millipore). Proteins were visualized using an Enhanced
Chemiluminescence kit (Intron, Seoul, Korea).
Statistical analysis
All data are presented as means ± SD. We performed a
Student t- test with a two-tailed distribution.
Results
Identification of genes that had lower transcript levels in
PC12 (WT-Akt) cells than in PC12 (DN-Akt) cells
We previously established stable PC12 cell lines that
constitutively overexpress WT-Akt1 or DN-Akt1 [3].
These sublines are designated as PC12 (WT-Akt) or
PC12 (DN-Akt). These two PC12 sublines have different
neurite outgrowth phenotypes from each other. PC12
(WT-Akt) cells barely differentiate in response to NGF,
whereas PC12 (DN-Akt) cells have an accelerated rate
of neurite outgrowth [3]. These two PC12 sublines were
chosen in the present study for this reason. We
a t t e m p t e dt of i r s tf i n dt h eg e n e st h a ta r ee x p r e s s e dd i f -
ferentially between the two subline cells and then iden-
tify those that are implicated in neuronal differentiation
among Akt-regulated genes. To this end, SSH was per-
formed using PC (DN-Akt) cells as a tester and PC
(WT-Akt) cells as a driver. Approximately 70 colonies
were isolated and amplified for sequencing. Semi-quan-
titative RT-PCR analysis validated the elevation of the
transcript levels of the majority of these genes in the
PC12 (DN-Akt) cells, as compared with the transcript
levels in PC12 (WT-Akt) cells (Fig. 1). These genes
could be categorized into five functional groups using
the Database for Annotation, Visualization and Inte-
grated Discovery (DAVID) [20]. These genes encode
Table 1 Primers used for semi-quantitative RT-PCR
Gene Forward primer Reverse primer
Ect2 5’-GAGAGCTGGCTGAAGATGCT-3’ 5’-TCCTCTGAGCTATGGGATG-3’
Cadm1 5’-TCTGGGCCAAACCTGTTCATC AAT-3’ 5’-CTGTGTCTGCGTCTGCTGCGTCAT-3’
Rgs4 5’-GTTGCTCCCGCTGCCTTTCTCT-3’ 5’-CATGTTCCGGCTTGTCTCCTCTC-3’
Cldnd1 5’-AACTTGGGATTGTGGAGACG-3’ 5’-CAGAGGTAGGTCCGAAGCAG-3’
Kntc2 5’-CCAGTTAGCTGTGCAGACCA-3’ 5’-CTTCAGACGTGCATTCCTCA-3’
Socs5 5’-GTGGACATGAACGCCAACAG-3’ 5’-AATCTCTGCGGCACAGTTTTG-3’
Pbrm1-predicted 5’-TGCCCTTGTCCTCCATAAAG-3’ 5’-AAAGTTCGGATCCACAGCAG-3’
Apool 5’-TGAAAAATGGGGTCATGGAT-3’ 5’-CTAATGTGGCCAGTCCCAGT-3’
MafK 5’-CCCAAGCCCAACAAGACATT-3’ 5’-GCTGCTTCAGCCGAGTTACC-3’
SytI 5’-CCGGACTGACTGATGGAGAAG-3’ 5’-ATCGGATGTACCCCCCATGT-3’
Syn-1 5’-CTCAAACTGCCTCTTCTGCTAATC-3’ 5’-ACTGTCCGTTCAAAGGGTCTATC-3’
Gapdh 5’-GGTTACCAGGGCTGCCTTCT-3’ 5’-ATGGGTTTCCCGTTGATGAC-3’
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cell communication, (2) the organization and localiza-
tion of cellular compartments and components, (3) gene
expression, (4) protein metabolism, and (5) developmen-
tal processes (Table 2).
Three genes, MafK, SytI,a n dSyn-1, in the fifth group of
clustering drew our interest because these genes are
known or presumed to be associated with neuronal func-
tion. MafK is one of the small Maf family proteins. It is
expressed in neural tissues of both late embryonal stage
and postnatal period, in the embryonic mesoderm, and in
mesenchymal and hematopoietic cells [21]. MafK certainly
plays a role in differentiation of these specific types of
cells; it participates in NGF-promoted neuritogenesis of
PC12 cells and immature telencephalon neurons [22], and
is required for erythroid differentiation [23]. SytI is abun-
dant in the synaptic vesicles of neurons, where it acts as a
calcium sensor and plays a critical role in neurotransmitter
release [24,25]. Its expression was shown to be induced in
neural crest cultures by BMP4, a factor that evokes nora-
drenergic differentiation [26,27]. Syn-1 is involved mainly
in the regulation of plasma membrane dynamics in neuro-
nal as well as non-neuronal cells [28,29]. Ectopic expres-
sion of Syn-1 in neurons was shown to increase the
number of neuritic varicosities [30].
We performed quantitative RT-PCR to quantitate the
differences between transcript levels in three cell popu-
lations: PC12 (WT-Akt), PC12 (DN-Akt), and PC12
(parental). The transcript level of each gene in PC12
(WT-Akt) and PC12 (DN-Akt) cells was presented as a
fold change from that of the PC12 (parental) cells. As
s h o w ni nF i g .2 A ,a l lo ft h et h r e eg e n e se x h i b i t e d
increased transcript levels in both PC12 (DN-Akt) and
PC12 (parental) cells compared to PC12 (WT-Akt) cells.
The transcript levels of these genes seem inversely cor-
related with the Akt activity levels, being highest in
PC12 (DN-Akt) and lowest in PC12 (WT-Akt). The SytI
transcript was remarkably elevated, with an ~18-fold
increase in PC12 (DN-Akt) cells, compared to PC12
(WT-Akt) cells. The fold differences of other gene tran-
scripts were 2.7-4.3. To check whether detected changes
in the transcript levels are followed by changes in pro-
tein levels, western blot analysis was performed (Fig.
2B). In agreement with the transcript levels, MafK, SytI,
and Syn-1 protein levels were also higher in PC (DN-
Akt) cells than in PC (WT-Akt) cells.
Effect of an Akt-specific inhibitor on expression of MafK,
SytI, and Syn-1 genes in PC12 (WT-Akt) cells
As stated above, our experiments were based on two
Akt-manipulated PC12 sublines that turned out to have
Figure 1 Verification of genes identified from SSH by semi-
quantitative RT-PCR. WT, PC12 (WT-Akt) cells; DN, PC12 (DN-Akt)
cells.
Table 2 A list of representative genes that are upregulated in PC12 (DN-Akt) cells compared to PC12 (WT-Akt) cells
Functional classification Functional classification
Signaling cascades, Cell communication
Epithelial cell transforming sequence 2 oncogene (Ect2)
Regulator of G protein signaling 4 (Rgs4)
Mss4
Syntenin 1 (Syn-1)
Kinetochore associated 2_predicted (Kntc2)
Synaptotagmin I (SytI)
Connexin 45 (Cx45)
Organization and localization of cellular compartments and
components
SytI
Calnexin (Canx)
Cell adhesion molecule 1 (Cadm1)
Mss4
Syn-1
Kntc2
Not clustered
Caludin domain containing 1 (Cldnd1)
Similar to golli-interacting protein
DEAD box polypeptide 42
Apolipoprotein O-like (Apool)
Suppressor of cytokine signaling 5 (Socs5)
Sp3 transcription factor
Gene expression, Nucleic acid metabolism
DEAH box polypeptide 15
Polybromo 1_predicted (Pbrm1_predicted)
v-maf musculoaponeurotic fibrosarcoma oncogene homolog K (MafK)
RNA binding motif protein 3
Phosphatidylinositol glycan anchor biosynthesis, class O
Protein metabolism
SytI
Canx
SFRS protein kinase 2
Ect2
Methionine adenosyltransferase II, alpha (Mat2a)
Development of anatomical structure and nervous system, Developmental process,
Secretion
Canx
Cadm1
MafK
Syn-1
SytI
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other; cells overexpressing Akt do not differentiate well
but the other cells that express the dominant-negative
form of Akt make neurites quite well. However, the spe-
cificity of dominant-negative Akt alleles has been con-
tentious [31,32], and the parallel use of chemical
inhibitors has been perceived as a necessary experimen-
tal approach. Therefore, we aimed to determine whether
an Akt inhibitor would produce a phenotype similar to
that seen in cells expressing dominant-negative Akt. We
used the specific inhibitor AKTi-1/2 [33]. We treated
PC12 (WT-Akt) cells with 0.1, 1, or 10 μM of AKTi-1/
2. As shown in Fig. 3A, the activity of Akt (phosphory-
lated level of Akt on Ser-473) was decreased by AKTi-1/
2 in a concentration-dependent manner, indicating that
this agent works effectively as an Akt inhibitor in our
cell system. We next examined the effect of this Akt
inhibitor on neurite outgrowth of PC12 (WT-Akt) cells.
Consistent with a previous report [3], PC12 (WT-Akt)
cells did not differentiate in response to NGF. However,
addition of AKTi-1/2 resulted in a remarkable increase
in the number of cells that have visible neurites, and
this effect was dose-dependent on AKTi-1/2 (Fig. 3B).
This result together with that of the previous report
implies that Akt can affect the ability of PC12 cells to
neuronally differentiate in response to NGF.
We then measured the transcript levels of MafK, SytI,
and Syn-1 using semi-quantitative PCR. The transcript
level of each gene was proportionally increased by
AKTi-1/2 (Fig. 3C). We therefore decided to use 10 μM
AKTi-1/2 and analyzed the gene transcript levels using
quantitative RT-PCR. AKTi-1/2 treatment increased the
transcript levels of all three genes by 180-230% in PC12
(WT-Akt) cells (Fig. 3D) and by comparable amounts in
PC12 (parental) cells (data not shown). These data,
together, indicate that Akt downregulates the levels of
MafK, SytI, and Syn-1 transcripts.
Since the overall level of a gene transcript is deter-
mined by transcription and mRNA stability, we investi-
gated whether the elevated levels of gene transcripts in
PC12 (DN-Akt) cells are due to increased mRNA stabi-
lity in these Akt-downregulated cells. Gene transcript
decay assays employing the transcriptional inhibitor acti-
nomycin D revealed that the mRNA stability of MafK,
SytI,a n dSyn-1 does not differ between PC12 (WT-Akt)
and PC12 (DN-Akt) cells (data not shown). For this rea-
son, the different levels of transcripts for these genes in
PC12 (WT-Akt) and PC12 (DN-Akt) cells appear to
reflect altered levels of transcription between the two
cell populations.
Effect of a Gsk3b inhibitor on expression of MafK, SytI,
and Syn-1 genes in PC12 (DN-Akt) cells
Several transcription factors have been shown to be
regulated by Akt and its downstream effectors. Gsk3b is
one of the major molecules downstream of Akt. It phos-
phorylates and regulates transcription factors such as
CREB and NF-kB [34]. We tested whether the Gsk3b
pathway is involved in Akt-induced downregulation of
transcription for the genes examined here. PC12 (DN-
Akt) cells were treated with TWS119, a Gsk3b inhibitor
[35]. Before examining the effect of this inhibitor on the
transcript levels of the genes, we first wanted to deter-
mine whether this inhibitor would work actively as a
Gsk3b inhibitor under our experimental conditions. To
this end, we assayed the level of b-catenin, because b-
catenin is another well-characterized substrate of Gsk3b
and undergoes degradation upon phosphorylation [36].
As shown in Fig. 4A, TWS119 treatment of PC12 (DN-
Akt) cells resulted in an increase in the level of b-cate-
nin, indicating that TWS119 actively inhibits Gsk3b.
Under these conditions, the transcript levels of MafK
and Syn-1 were significantly lowered after treatment
with this Gsk3b inhibitor, while that of SytI was not
notably changed (Fig. 4B). This result suggests that the
reduction of MafK and Syn-1 expression by Akt occurs,
at least in part, through Gsk3b inhibition.
Knockdown of Syn-1 decreases the neurite
complexity in PC12 cells
We took an shRNA approach to knock down Syn-1 in
PC12 (DN-Akt) cells. Cells were transfected with
shControl, shSyn-1#1, or shSyn-1#2. By semiquantitative
and quantitative RT-PCR and western blot analysis, we
found an efficient knockdown of Syn-1 transcript and
protein in cells transfected with shSyn-1#2 as compared
with shControl-transfected cells (Fig. 5). We thus ana-
lyzed several aspects of neurite outgrowth in PC12 (DN-
Figure 2 Analyses of MafK, SytI,a n dSyn-1 mRNA levels in
parental, WT-Akt-expressing, and DN-Akt-expressing PC12
cells. (A) Quantitative RT-PCR. mRNA level of the gene in each
group of cells was normalized to the level of GAPDH mRNA and
the transcript level of each gene in PC12 (WT-Akt) and PC12 (DN-
Akt) cells is presented as a fold change from that of the PC12
(parental) cells. Parental, PC12 (parental) cells. *P < 0.05 (parental vs.
WT). *P < 0.05 (parental vs. DN). n = 3-4, mean + SD. (B) Western
blot analysis of SytI and Syn-1 protein levels in PC12 (WT-Akt) and
PC12 (DN-Akt) cells.
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pically observed that cells transfected with this shRNA
possessed less elaborate neurites compared to control
cells (Fig. 6A). The number of neurites originating from
the cell body of neuritogenic cells was decreased in cells
where Syn-1 was knocked down (Fig. 6B). Cells trans-
fected with shSyn-1 had 1.74 ± 0.15 whereas control
cells had 2.80 ± 0.20 neurites per cell on the 5
th day of
NGF treatment. Another neurite outgrowth feature was
also observed to be altered by Syn-1 knockdown. As for
the neurite number, neurite branching was significantly
reduced in cells transfected with shSyn-1 as compared
with that of control cells (Fig. 6C). 64.5% of neurites
from the control cells had at least one branch point, but
only 26.5% of Syn-1-knockdown cell neurites displayed
branching. Unlike these effects on the neurite network,
however, the number of cells bearing at least one neur-
ite was not altered noticeably by Syn-1 knockdown (Fig.
6D). These data demonstrate that Syn-1 does not affect
neurite initiation but rather it promotes neurite profu-
sion and branching in PC12 cells.
Discussion
In this study, we identified novel Akt-regulated genes,
MafK, SytI,a n dSyn-1. We showed that the transcript
levels of these three genes were lower in PC12 (WT-
Figure 3 Effect of the Akt inhibitor AKTi-1/2 on mRNA levels for the MafK, SytI,a n dSyn-1 genes. (A) Western blot analysis of pAkt(Ser-
473) protein level in PC12 (WT-Akt) cells treated with various concentrations of AKTi-1/2 prior to 10 min treatment with NGF. (B) The percentage
of neuritogenic PC12 (WT-Akt) cells treated with or without AKTi-1/2. Averages and standard deviations are derived from more than six fields of
view. *P < 0.001 (n = 6-9, mean + SD). (C) Semi-quantitative RT-PCR. PC12 (WT-Akt) cells were treated with various concentrations of AKTi-1/2.
(D) Quantitative RT-PCR. PC12 (WT-Akt) cells were treated with 10 μM of AKTi-1/2. The mRNA level is presented as a fold difference over that of
vehicle-treated cells. *P < 0.05 (n = 3-4, mean + SD). (E) Western blot analysis of SytI and Syn-1 protein levels in PC12 (WT-Akt) cells treated with
vehicle (Veh) or 10 μM AKTi-1/2.
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following treatment with an Akt inhibitor. Taken
together, these results indicate that Akt downregulates
the expression of MafK, SytI,a n dSyn-1. MafK and SytI
are involved in certain aspects of neuronal function.
Inhibition of MafK expression has been reported to sup-
press neurite generation in PC12 cells treated with NGF
and in primary immature neuronal cells [22], and mice
deficient in MafK and MafG suffer from neurological
dysfunction [37]. SytI is a synaptic vesicle protein in
neurons. It acts as a calcium sensor and plays a role in
neurotransmitter release [24,25]. Syn-1 interacts with a
plethora of proteins via its PDZ domains and regulates
transmembrane-receptor trafficking, tumor-cell metasta-
sis, and probably neuronal-synaptic function [29]. The
neuronal action of Syn-1 has been somewhat speculative
and is based on the following findings. Syn-1 binds to
several proteins implicated in axon outgrowth, fascicula-
tion, and/or guidance, including Unc51.1 [38], ephrin
receptors [39] and neurofascin [40]. Moreover, Syn-1
was shown to be expressed maximally in periods of
intense growth and synapse formation during neuron
development and its ectopic overexpression increased
the number of short dendritic varicosities in neurons
[30]. Here, we examined whether Syn-1 could affect the
outgrowth of neurites. We transfected PC12 (DN-Akt)
cells with a hairpin siRNA directed against Syn-1. This
shRNA effectively reduced the endogenous level of Syn-
1. We showed that a decreased Syn-1 level led to a
decrease in the number of neurites and the percentage
Figure 4 Effect of a Gsk3b inhibitor on gene expression in PC12 (DN-Akt) cells. PC12 (DN-Akt) cells were treated with 10 μM TWS119, a
Gsk3b inhibitor for three hours. (A) Western blot analysis of b-catenin in PC12 (DN-Akt) cells treated with TWS119 to confirm that this agent
works actively as a Gsk3b inhibitor in our experimental conditions. (B) mRNA levels for each gene are presented as a fold difference over that of
vehicle-treated cells. *P < 0.05 (n = 3-4, mean + SD). (C) Western blot analysis of Syn-1 protein. Veh, vehicle; Inh, inhibitor.
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ever, overexpression of Syn-1 in mature cultured hippo-
campal neurons was reported not to affect the number
of branches [30]. This discrepancy may be due to the
different levels of Syn-1 signaling, resulting from
decreased or elevated expression of Syn-1, or reflect dif-
ferences between mature hippocampal cells and neuro-
blast PC12 cells. When PC12 (DN-Akt) and PC12
(parental) cells were compared, it was also noticed that
PC12 (parental) cells have fewer neurite branch points
than PC12 (DN-Akt) cells (data not shown). These
results suggest that Syn-1 has a role in producing pro-
fuse neurites. Though Syn-1 has been implicated in neu-
ronal membrane varicosities [30], its Namikawa et al.
2000 K. Namikawa, M. Honma, K. Abe, M. Takeda, K.
Mansur, T. Obata, A. Miwa, H. Okado and H. Kiyama,
Akt/protein kinase B prevents injury-induced moto-
neuron death and accelerates axonal regeneration, J.
Neurosci. 20 (2000), pp. 2875-2886. View Record in Sco-
pus | Cited By in Scopus (108)effect on neurite branch-
ing has not been described.
There have been conflicting reports regarding the role
of Akt in neuronal outgrowth/differentiation. Several
studies have reported a negative impact of Akt upon
neuronal differentiation [2-6], while others published
opposite results [41,42]. The reason for this discrepancy
is not known. The direction of Akt’s effect on neuronal
differentiation probably depends on the state/context of
cells. In fact, signaling molecules have been shown to
induce different phenotypes, depending on the cellular
stage/context. For instance, phosphoinositide 3-kinase
has been shown to be required for NGF-induced differ-
entiation of PC12 cells [43], however the same results
were not observed by other research group [44]. It may
be that the same signaling molecule has different sensi-
tivity to its interacting partners under different cell con-
texts, producing different outcomes. It has been
reported that Ras responds only to phosphoinositide 3-
kinase of the basal rather than stimulated state under
certain circiumstances [45]. Another example is Akt and
Raf-MEK-MAPK pathways. Akt interacts with and inhi-
bits the Raf-MEK-MAPK pathway [46], but this interac-
tion occurs only in certain stages of cell differentiation
[47]. The strength and duration of a molecule’s signaling
can be affected by its interacting proteins, which them-
selves also have changing activity and duration. There-
fore, the signaling strength and duration of Raf-MAPK,
which mediates neuronal differentiation when activated
sustainedly [48,49], could be controlled by Akt. It has
been suggested that a high level of Akt activity inhibits
cell differentiation, whereas low Akt activation levels
may be permissive or necessary for cell differentiation
[2]. Furthermore, depending on the different level of
Raf-MAPK, even the same level of Akt activity would
produce different outcomes.
How Akt regulates neuronal outgrowth/differentiation
has not been resolved. In the present study, we demon-
strate that Akt downregulates the expression of several
genes of neuronal functions, including MafK, SytI,a n d
Syn-1, and some other genes such as Canx and Cadm1
(Table 2). It can be envisioned from these results that
Akt-mediated downregulation of these genes of neuronal
Figure 5 shRNA expression vector against Syn-1 reduces the
endogenous Syn-1 transcript and protein levels. PC12 (DN-Akt)
cells were infected with lentiviral shSyn-1#1, #2 or shControl (shCtrl).
Syn-1 transcript was detected by semi-quantitative (A) and real-time
(B) RT-PCR. (C) Western blot analysis.
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neuronal phenotype in cells overexpressing Akt. Akt is
often found activated in some neuroblastomas [50,51] as
well as many other human cancers [52,53]. Neuroblasto-
mas with hyperactive Akt or with low potential to differ-
entiate in response to neurotrophins show poor
prognosis [50,54]. There might be a causal connection
between the Akt activity and the differentiation ability
in these neuroblastomas. We observed that incubation
of PC12 (WT-Akt) cells with the Akt inhibitor AKTi-1/
2 restored their neurite outgrowth responsiveness to
NGF (Fig. 3B). In this respect, a use of an Akt inhibitor
like AKTi-1/2 would be advantageous in that it can not
only possess the cytotoxic effect but can also lead the
cells to respond to the differentiation effect of
neurotrophins.
The mechanism of the downregulation of MafK, SytI,
and Syn-1 genes by Akt remains unclear. However, the
increased expression of MafK and Syn-1 genes in PC12
(WT-Akt) cells upon pharmacological inhibition of
Gsk3b (Fig. 4) indicates that Gsk3b somehow regulates
the transcription factors for these two genes. Gsk3b
phosphorylates several transcription factors, including
A P - 1 ,C R E B ,H S F - 1 ,N F A T ,C / E B P ,a n dN F - k B[ 3 4 ] ,
Ngn2 [55], and Smad3/4 [56]. The functional conse-
quence of this interaction with Gsk3b differs among
transcription factors. While most are inhibited by
Gsk3b, the transcriptional activity of C/EBP and Ngn2
is increased by Gsk3b. Since Akt phosphorylates and
inhibits Gsk3b, the transcriptional activity of C/EBP
and Ngn2 might be downregulated in PC12 (WT-Akt)
cells but upregulated in PC12 (DN-Akt) cells. In this
Figure 6 Knockdown of endogenous Syn-1 by shRNA decreases the numbers of neurites and branches.P C 1 2( D N - A k t )c e l l sw e r e
infected with lentiviral shSyn-1#2 or shControl. (A) Fluorescent microscopic photographs of cells treated with NGF for 5 days. Scale = 50 μm. (B)
The number of neurites originating from the neuritogenic cell body. (C) The percentage of branch-bearing neurites. (D) The percentage of
neuritogenic cells among GFP-positive cells. Averages and standard deviations are derived from more than ten fields of view. * P < 0.001 and
# P < 0.01 (n = 10-15, mean + SD).
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Syn-1 gene expressions are altered by expressing the
active or dominant-negative (or silencing) form of C/
EBP and Ngn2 in PC (WT-Akt) and PC (DN-Akt)
cells, respectively. Our work indicates that the Gsk3b
pathway does not appear to be implicated in the
decreased expression of SytI in PC12 (WT-Akt).
Expression of SytI in sympathetic neurons has been
shown to be induced by BMP4 [27], and BMP4 signal-
ing is known to be mediated by Smad proteins and
MAPKs [57,58]. Therefore, it can be suggested that
decreased expression of SytI in PC12 (WT-Akt) cells
might be due to the Akt-mediated inhibition of the
Raf-MAPK pathway. Alternatively, Akt might directly
affect the transcription factor responsible for SytI
expression. This could be Brn3, because this is the
only transcription factor identified so far that could
increase the expression of SytI in neuronal cells [59],
and interestingly it has the preferred phosphorylation
motif of Akt [31].
Conclusion
Using PC12 cells expressing wild-type or dominant-
negative Akt and also using a pharmacological inhibitor
of Akt, we demonstrate that Akt can negatively affect
the expression of MafK, SytI,a n dSyn-1 genes. MafK
and SytI have been known to positively affect neuronal
differentiation or neurotransmitter release. As for Syn-1,
we observed here that Syn-1 has a role in producing
profuse neurites. We also show that treatment with Akt
inhibitor resulted in an improvement of neurite out-
growth. In summary, Akt regulates the expression of
MafK, SytI,a n dSyn-1, which are all neuronal function-
related genes.
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